GLP-1, GIP and Glucagon Receptors: A Primer on Incretin Research Peptides

Few areas of peptide research have moved as quickly as incretin biology. Over the past two decades, research has gone from peptides that activate one receptor to compounds designed to activate two or three. This primer explains the receptors involved and the main types of agonists used in the lab.

What incretins are

Incretins are hormones released by the gut after a meal. The two best known are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both act on G protein-coupled receptors (GPCRs), and both are part of what researchers call the "incretin effect": the observation that glucose taken by mouth triggers a larger insulin response than the same amount given intravenously.

The three receptors

GLP-1 receptor (GLP-1R)

GLP-1R is found in the pancreas, brain, gut and other tissues. In research models, it is studied for its roles in glucose-dependent insulin secretion, gastric emptying and appetite-related signaling in the brain. Native GLP-1 breaks down within minutes because the enzyme DPP-4 degrades it, so research analogs are modified to last longer.

GIP receptor (GIPR)

GIPR is found in the pancreas, fat tissue and the brain. Its role has been debated: some studies focus on its insulin-releasing effects, others on its effects on fat tissue. Interest in GIPR grew when dual agonists that combined GIP and GLP-1 activity produced results in research settings that differed from GLP-1 activation alone.

Glucagon receptor (GCGR)

Glucagon is not an incretin. It is released by the pancreas and generally opposes insulin by raising blood glucose. The glucagon receptor is studied for its effects on liver metabolism and energy expenditure. Combining glucagon receptor activity with incretin receptor activity is the idea behind triple agonist research.

Single, dual and triple agonists

• Single agonists target one receptor, most often GLP-1R. They are the reference point other compounds are compared with.
• Dual agonists activate two receptors with one molecule. Tirzepatide, which acts on GIPR and GLP-1R, is the most widely studied example.
• Triple agonists add glucagon receptor activity to GIP and GLP-1 activity. RTD-3 is supplied for research into this triple-agonist approach.

Because one molecule activates several receptors, researchers pay close attention to how strongly it acts on each receptor compared with the others. Two compounds that hit the same receptors can behave differently in a model if that balance differs.

How these peptides are engineered

Most incretin research peptides start from a natural hormone sequence. Chemists then make changes to resist DPP-4 breakdown and extend half-life. A common approach is attaching a fatty acid side chain that binds albumin, which slows clearance. These modifications make the peptides larger and more complex, so identity confirmation by mass spectrometry is especially important for this class. See HPLC vs. LC-MS for why.

Handling notes

Like other lyophilized peptides, incretin analogs should be stored cold and protected from light and moisture, and reconstituted vials should be kept refrigerated. Our storage and handling guide covers the details.

Browse our Incretin Research Peptides collection, and check batch documentation in the COA lookup.

All Azyrion Labs products are for laboratory research use only. Not for human or veterinary use. Nothing in this article is medical advice.